Glial cells, the brain's supporting tissue, give rise to gliomas, which are brain tumours. Glioblastoma multiforme is the most prevalent and dangerous variety of glioma (GBM). First, surgery is used to remove as much of the tumour as feasible, then radiation therapy (60 Gy in 30 fractions) and chemotherapy (concurrent and adjuvant temozolomide) are used for Recurrent Glioblastoma Multiforme Treatment (NCCN 2018). The duration of the initial course of treatment is roughly nine months. In reasonably fit individuals under the age of 70, chemotherapy has been linked to median progression-free survival of 6.5 months and median overall survival of 14.6 months. Two years after diagnosis, 25% of patients having chemoradiotherapy are likely to still be alive, compared to 10% of those receiving radiotherapy alone.
Read More- https://coherentmarketinsightsus.blogspot.com/2023/02/other-malignancies-and-recurrent.html
